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Abstract
We have studied the physiological and clinical relevance of
measurements of serum total and free IGF-I and IGF-
binding protein-3 (IGFBP-3) in 57 previously untreated
patients with active acromegaly (32 males, 25 females;
mean age 47 years) as compared with sex- and age-
matched normal healthy controls. Serum total and free
IGF-I, but not IGFBP-3, are suitable biochemical
parameters for screening for acromegaly. In acromegalics,
the mean 24 h serum GH, total IGF-I and IGFBP-3 levels
tend to decrease with age. However, in our series of
patients, mean 24 h serum GH levels, IGFBP-3, total and
free IGF-I do not correlate with disease activity in
acromegaly.
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Introduction
In normal healthy adults, spontaneous growth hormone
(GH) secretion shows a diurnal pattern and is influenced
by age and sex. More than 99% of GH is secreted in a
pulsatile fashion. In patients with active acromegaly, only
50% of GH secretion is excreted in a pulsatile manner, but
the GH pulse frequency is increased as compared with
normal healthy adults (van den Berg et al. 1994). Because
of the variability in GH secretion over the day and the
short half-life of GH (approximately 20 min) in the
circulation, random GH measurements have only limited
value for the diVerential diagnosis of acromegaly. Gener-
ally, ‘undetectable’ GH levels measured with a standard
commercially available RIA or IRMA in a patient sus-
pected of having acromegaly exclude the diagnosis. How-
ever, it should be noted that the actual GH level in this
situation may not really be zero, but below the sensitivity
level of the assay. In contrast, spontaneous, exercise-
induced, or postprandial GH pulses during the day may
occasionally result in an abnormally high random GH
determination in a normal subject. Using 24 h GH levels,
a good separation can be made between patients with
active acromegaly and normal subjects, but only after
matching for age (Ho & Weissberger 1994). In normal
subjects, serum GH levels (measured with a commercially
available RIA) are suppressed to <2 µg/l (<4 mU/l)
within 1–2 h of the administration of an oral load of
75–100 g glucose after overnight fasting. However, in
acromegaly there is a failure to suppress GH levels to this
value during oral glucose tolerance testing or they even
show a paradoxical rise (Melmed 1990, Melmed et al.
1995).
Insulin-like growth factor-I (IGF-I), formerly known as
somatomedin-C, mediates many of the actions of GH. GH
induces IGF-I synthesis and release, especially from the
liver. In contrast with serum GH levels, serum (total)
IGF-I levels show little fluctuation during the course of the
day. Serum (total) IGF-I levels are invariably elevated in
active acromegaly (Clemmons et al. 1979). Pregnancy and
late puberty are also associated with elevated serum (total)
IGF-I levels. A highly significant correlation exists be-
tween serum (total) IGF-I levels and the area under the
serum GH curve estimated during oral glucose tolerance
testing (r=0·66) (Dobrashian et al. 1993). A positive
correlation has also been demonstrated between the
mean 24 h serum GH levels and serum (total) IGF-I
levels. The relationship between mean serum GH levels
either during oral glucose tolerance testing or in a 24 h
profile and serum (total) IGF-I levels shows a curvilinear
pattern. A linear relationship exists between GH levels
<10 µg/l (<20 mU/l) and serum (total) IGF-I. Serum
(total) IGF-I levels reach their maximum at serum
GH levels >20 µg/l (>40 mU/l) (Barkan et al. 1988,
Dobrashian et al. 1993).
The majority of IGF-I (and IGF-II) in the serum is
complexed with binding proteins (IGFBPs). In the circu-
lation, about 75% of the IGFs are complexed with
IGFBP-3 and an acid-labile subunit in a 150–200 kDa
ternary complex. The remainder of the circulating IGFs is
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either bound to lower molecular mass IGFBPs or circulates
in the free form. IGFBP-3 appears to be the primary
regulator of IGF bioavailability in response to changes in
circulating GH levels (Baxter 1994). The ternary complex
does not cross the vascular endothelium and therefore
serves as a reservoir for IGFs. When associated with the
ternary complex, the half-life of the IGFs is prolonged.
Breakdown of the IGFBPs is regulated by IGFBP pro-
teases. An increase in IGFBP-3 proteolysis will lead to
increased formation of lower molecular mass IGF–IGFBP
complexes, which are capable of crossing the endothelium.
Elevated IGFBP-3 levels have been found in patients with
active acromegaly (de Herder et al. 1995, Grinspoon et al.
1995). The 28 kDa IGFBP-1 appears to be the primary
regulator of IGF bioavailability in response to the changes
in the circulating insulin level (Baxter 1994). Serum
levels of IGFBP-5, but not IGFBP-4, show significant
positive correlations with the IGFs. IGFBP-1 and IGFBP-4
in serum have predominant IGF-I inhibitory activities,
whereas IGFBP-5 in serum has IGF-I stimulatory activities
(Mohan et al. 1996).
By analogy with steroid and thyroid hormones, the
unbound fraction may be the dominating fraction for the
biological activity of IGF-I. Frystyk et al. (1994) have
shown that fasting serum free IGF-I levels are increased
in acromegaly and showed no overlap with levels found in
healthy controls.
We have studied the physiological and clinical relevance
of measurements of serum total and free IGF-I and
IGFBP-3 in acromegaly as compared with normal healthy
adults.
Patients and methods
Fifty-seven previously untreated patients (32 males, 25
females; mean age 47 years) with active acromegaly were
studied. Disease activity was scored according to five
clinical parameters: excessive sweating, headaches, fatigue,
paresthesias and arthralgias (see Table 1). Fifty-seven sex-
and age-matched adults were studied as controls. In
patients with acromegaly, serum GH was sampled from
0800 to 1800 h at hourly intervals, followed by 2 hourly
sampling to 0600 h. A final sample was taken at 0700 h.
Fasting samples for measurements of IGF-I, IGFBP-3 and
free IGF-I were taken from acromegalics and healthy
controls.
Serum GH was measured by IRMA supplied by CIS
Bio International, Gif-sur-Yvette Cedex, France (intra-
assay coeYcient of variation (CV) 2·8%, interassay CV
4·4%). Serum total IGF-I was determined by RIA using
kits obtained from Medgenix Diagnostics, Fleurus,
Belgium (intra-assay CV 6·1%, interassay CV 9·9%).
Serum free IGF-I was measured by IRMA supplied by
Diagnostic Service Laboratories, Webster, TX, USA
(intra-assay CV 10·3%, interassay CV, 10·7%).
Serum IGFBP-3 levels were determined by IRMA
supplied by Diagnostic Service Laboratories (intra-assay
CV 3·9%, interassay CV 1·9%).
Figure 1 (a) Serum total IGF-I and (c) serum IGFBP-3 in 57
patients with active acromegaly and 57 sex- and age-matched
healthy adults. (b) Serum free IGF-I in 33 patients with active
acromegaly and 33 sex- and age-matched healthy adults.
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Results
In Fig. 1a–c, serum total IGF-I, free IGF-I and IGFBP-
3 levels in normal healthy controls and patients with
active acromegaly are shown. There was a consider-
able overlap for serum IGFBP-3 levels between nor-
mals and acromegalics, but not for serum total and free
IGF-I.
Figure 2A–D shows the relations between age and
mean 24 h serum GH, total IGF-I, free IGF-I and
IGFBP-3 levels in patients with active acromegaly. Mean
24 h serum GH, serum total IGF-I and IGFBP-3 levels
decrease with increasing age. However, there is no
relation between serum free IGF-I levels and age in
acromegalics.
In Table 2, the correlations between mean 24 h serum
GH levels and serum total IGF-I, free IGF-I and IGFBP-3
are shown. There was a significant correlation between
mean 24 h serum GH levels and serum total IGF-I levels
(r=0·38, P=0·005; non-parametric correlation (Spearman)).
Table 1 Clinical activity score in acromegaly. Total score: <3, mild; 3–5, moderate;
>5, severe
Headaches Fatigue Perspiration Paresthesias Arthralgia
Score
0 None None None None None
1 Mild Mild Mild Mild Mild
2 Moderate Moderate Moderate Moderate Moderate
3 Severe Severe Severe Severe/CTS Severe
CTS, carpal tunnel syndrome.
Figure 2 Relations between (A) serum IGFBP-3 and age (r="0·25, P=0·02), (B) mean 24 h serum GH and age (r="0·29, P=0·002),
(C) serum total IGF-I and age (r="0·30, P=0·02) and (D) serum free IGF-I and age (not significant) in 57 patients with active acromegaly
(non-parametric correlation (Spearman)). Statistical significance was defined as P<0·05.
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There was no significant correlation between mean 24 h
serum GH and serum free IGF-I or serum IGFBP-3 levels.
There was a significant correlation between serum total
IGF-I and serum IGFBP-3 levels (r=0·55, P<0·001;
non-parametric correlation (Spearman)), but not between
serum total and free IGF-I levels. Also, no significant
correlation was found between serum free IGF-I and
IGFBP-3 levels.
Table 2 Correlations between the various clinical and biochemical parameters in 57 patients with active acromegaly (non-parametric
correlation (Spearman)). Statistical significance defined as P<0·05 (NS, not significant)
Total IGF-I IGFBP-3 Free IGF-I Disease activity Mean 24 h GH
Age "0·28 (P=0·04) "0·28 (P=0·04) "0·13 (NS) "0·46 (P<0·001) "0·40 (P=0·003)
Total IGF-I 0·55 (P<0·001) 0·12 (NS) 0·18 (NS) 0·38 (P=0·005)
IGFBP-3 0·01 (NS) 0·06 (NS) 0·21 (NS)
Free IGF-I 0·01 (NS) 0·26 (NS)
Disease activity 0·10 (NS)
Figure 3 Relations between (A) serum free IGF-I and clinical activity (not significant), (B) serum total IGF-I and clinical activity (not
significant), (C) serum IGFBP-3 and clinical activity (not significant) and (D) mean 24 h serum GH and clinical activity (not significant) in 57
patients with active acromegaly (non-parametric correlation (Spearman)). Statistical significance was defined as P<0·05.
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Figure 3A–D shows the correlations between disease
activity and mean 24 h serum GH, free and total IGF-I
and IGFBP-3 levels. Mean 24 h serum GH, free and total
IGF-I and IGFBP-3 levels did not correlate with disease
activity.
Discussion
By comparing a large series of patients with untreated
acromegaly with sex- and age-matched controls, the
present study has shown a considerable overlap of serum
IGFBP-3 levels, but not of free and total IGF-I levels
between the controls and acromegalics. This is in line with
our previous findings in a smaller group of patients with
acromegaly (de Herder et al. 1995). Therefore IGFBP-3 is
not a marker for the assessment of GH excess in adults.
Both serum free and total IGF-I measurements can serve
this purpose better.
Our results show that in acromegalics, mean 24 h serum
GH, total IGF-I and IGFBP-3 levels tend to decrease with
age. This is also in line with our previous observations (van
der Lely et al. 1992, de Herder et al. 1995). We could not
demonstrate a decrease in serum free IGF-I with age. This
might be explained by a parallel decrement in f total IGF-I
and IGFBP-3.
We have shown that mean 24 h serum GH levels,
IGFBP-3, total and free IGF-I do not correlate with
disease activity in acromegaly.
Conclusions
Serum total and free IGF-I, but not IGFBP-3, are suitable
biochemical parameters for screening for acromegaly.
In acromegalics, mean 24 h serum GH, total IGF-I and
IGFBP-3 levels tend to decrease with age.
Mean 24 h serum GH, total and free IGF-I and
IGFBP-3 levels do not correlate with disease activity in
acromegaly.
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Discussion: IGF-I levels and diagnosis
Dr M Besser (London, UK):
I wonder if one has not to be very careful about tautological arguments, in that,
as I recall, the GH levels in your patients were really rather high. Did anyone in
your group have a mean serum GH level of about 10 mU/l (5 µg/l)? Weren’t
they all 50 mU/l (25 µg/l) or more?
Dr A J van der Lely (Rotterdam, The Netherlands):
No; the range was quite wide (up to 400 µg/l and down to below 10 µg/l).
Besser:
Did you have anyone down at 10 mU/l (5 µg/l)? We quite often see patients in
whom it is clinically very diYcult to make the diagnosis, and they never have
blood levels below 1 mU/l (0·5 µg/l); those are the patients in whom the IGF-I
concentration is not helpful, and yet they improve dramatically with octreotide
treatment. I would agree with you that there is a correlation between GH and
IGF-I, but this does not help with individual patients who have very mild
acromegaly at presentation. In our experience IGF-I is not helpful in low levels
at diagnosis, whereas severe acromegaly can be diagnosed on the basis of a single
blood sample.
van der Lely:
There are many acromegalics who have a relatively low GH secretion and a
considerable amount of IGF-I, and vice-versa. Up to now we have not been able
to show specific clinical characteristics between such groups.
Dr J A H Wass (Oxford, UK):
To change subject, your interesting data on serum levels of free IGF-I do not
appear — rather surprisingly — to go down with age. How do you explain that
in terms of the known decline in secretion of GH with age?
van der Lely:
I cannot explain it; that is what we found.
Dr A Barkan (Ann Arbor, USA):
First of all, I completely agree that serum IGF-I level is by far the most sensitive
screening test. We have seen many patients with de novo untreated acromegaly,
with GH fluctuations between 0·5 and 2 µg/l, who were clinically active and
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whose IGF level was extremely high. We have yet to see a patient with
acromegaly whose IGF-I level is within the so-called normal range.
Dr H-J Quabbe (Berlin, Germany):
With reference to the negative correlation between clinical score and age of the
patient, I tend to believe that older patients probably have a long duration of a
very mild case of acromegaly. I think that many of these patients developed
tumours at the age of 25–30 years, but that the tumours had very low secretory
activity. Have you any information on the estimated duration of disease in these
older patients?
van der Lely:
They tend to have longer disease activity than the younger patients but, strangely,
tumour volume in older patients is less than that in younger patients, which is
inexplicable on the premise that older patients just have the same disease for a
longer period.
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